What is Journey Medical Corporation's (DERM) StockRank?

MoatMap's StockRank for Journey Medical Corporation (DERM) is 19/100, with a Strong Sell signal. This is a composite score combining Quality (37), Value (28), and Momentum (39) factor ranks across MoatMap's 20,000+ stock universe.

Does Journey Medical Corporation have an economic moat?

Journey Medical Corporation (DERM) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Journey Medical Corporation a buy, hold, or sell?

MoatMap's current signal for Journey Medical Corporation (DERM) is Strong Sell, based on a StockRank of 19/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Journey Medical Corporation in?

Journey Medical Corporation (DERM) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

DERM

STRONG SELLREMOVE

Journey Medical Corporation · Healthcare · United States · $180M · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

-36.6%

D/E

0.8x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Journey Medical is a specialty pharmaceutical company focusing on dermatology. It lacks the scale, pricing power, and R&D reinvestment runway of a true compounder, with no connection to our CDMO pricing power theme.

COMPANY DESCRIPTION

Journey Medical Corporation is a pharmaceutical company focused on the acquisition, development, and commercialization of branded and generic dermatology products. The company aims to provide innovative solutions for various skin conditions, leveraging a focused sales force to target dermatologists and primary care physicians. Its strategy of acquiring established products and developing new formulations provides a niche within the competitive dermatology market.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	73.7M	79.2M	56.1M	61.9M	-5.7%
EPS	-1.69	-0.21	-0.72	-0.47	—
Shares	17.8M	19.3M	22.2M	27.1M	+52.8%
Debt	23.0M	14.7M	25.1M	25.4M	3.4%
Equity	17.0M	20.4M	20.1M	31.9M	23.3%
Op CF	-13.5M	5.2M	-9.1M	-12.4M	—
Inv CF	-20.0M	-5.0M	-15.0M	0	—
Fin CF	16.5M	-4.8M	17.0M	16.2M	—

PRICE (1Y)+36.7%

SMA 50SMA 200

$6.85

RSI (14)

66.8

52W High

$9.56

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-13.4%31.8

ROE

-36.6%22.5

GP/Assets

44.7%82.5

Op. Margin

-9.3%29.6

FCF/Assets

-3.5%38.9

Piotroski

430.3

Int. Cover

-2.1x32.2

D/E Ratio

0.83x19.0

Current Ratio

1.72x30.9

Value

P/E (TTM)

—N/A

EV/EBITDA

-83.9x25.0

P/FCF

—N/A

P/B

5.7x23.1

P/S

2.7x59.1

Div Yield

—N/A

Momentum

52W High %

72%48.2

RS 6M

-21%39.9

SMA 50/200

0.81x12.4

EPS Rev 4W

0.0%49.2

EPS Rev 12W

—N/A

EPS Improve

+84%67.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$180M

P/E (Forward)

-106.3x

Gross Margin

65.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DERM are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DERM	Journey Medical Corporation(you)	$180M	19	STRONG SELL
AKBA	Akebia Therapeutics, Inc.	$299M	18	STRONG SELL
LFCR	Lifecore Biomedical, Inc.	$207M	10	STRONG SELL
JUSH.CN	Jushi Holdings Inc.	$93M	25	SELL
TKNO	Alpha Teknova, Inc.	$272M	32	SELL
CL.CN	Cresco Labs Inc.	$293M	31	SELL
ORGO	Organogenesis Holdings Inc.	$309M	31	SELL
CWEB.TO	Charlotte's Web Holdings, Inc.	$74M	30	SELL
EOLS	Evolus, Inc.	$432M	32	SELL
VREO.CN	Vireo Growth Inc.	$532M	28	SELL

Peer medians: ROE -23.1% · P/E 25.2x · Gross margin 44.3%

Journey Medical Corporation (DERM) — Stock Score Summary

Journey Medical Corporation (DERM) has a MoatMap StockRank of 19/100 based on Quality (37/100), Value (28/100), and Momentum (39/100) factor scores. The current signal is STRONG SELL. Journey Medical is a specialty pharmaceutical company focusing on dermatology. It lacks the scale, pricing power, and R&D reinvestment runway of a true compounder, with no connection to our CDMO pricing power theme.

Key Financial Metrics

Price	$6.85
Market Cap	$180M
P/E (Forward)	-106.33
Price/Book	5.66
Return on Equity	-36.6%
Return on Invested Capital	-13.4%
Debt/Equity	82.60
Gross Margin	65.4%
Operating Margin	-9.3%
Revenue Growth	21.5%
Free Cash Flow	$-3M

Journey Medical Corporation operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Journey Medical Corporation’s (DERM) StockRank?: MoatMap’s StockRank for Journey Medical Corporation (DERM) is 19/100, with a Strong Sell signal. It is a composite of Quality (37), Value (28), and Momentum (39) factor ranks across MoatMap’s 20,000+ stock universe.
Does Journey Medical Corporation have an economic moat?: Journey Medical Corporation (DERM) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Journey Medical Corporation a buy, hold, or sell?: MoatMap’s current signal for Journey Medical Corporation (DERM) is Strong Sell, based on a StockRank of 19/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Journey Medical Corporation in?: Journey Medical Corporation (DERM) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).